Bedford, United States
Instylla, founded in 2017 and headquartered in the United States, is at the forefront of revolutionizing the biotechnology and medical devices industries. With its slogan, “Materializing Solutions™️”, the company is dedicated to producing next-generation liquid embolics aimed at enhancing interventional radiology. Its primary clinical applications are focused on interventional oncology and peripheral hemostasis, reflecting a strong commitment to advancing medical solutions.
In a notable financial development, Instylla secured a significant $30.00M Late VC investment on 01 August 2023. This funding round was led by prominent investors, including Delos Capital, Excelestar Ventures, Incept LLC, and AMED Ventures. These investments underscore the confidence in Instylla's innovative capabilities and indicate robust potential for growth in the biotech and medical device sectors. The company stands as a promising candidate for further investment, with its cutting-edge approach and strong market position.
